Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini Piramal

Time of India

3 days ago

Piramal Healthcare
will focus on organic expansion as its primary growth driver for the next 4-5 years, while it looks for licensing of product acquisition deals in both complex hospital generics and consumer healthcare business, chairperson
Nandini Piramal
told ET in an interaction.
She reiterated the company's revenue target of $2 billion by FY30 despite macroeconomic volatility and sector-specific headwinds.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
others
Project Management
Management
Technology
Product Management
Finance
Public Policy
PGDM
Degree
Data Science
Design Thinking
Artificial Intelligence
MBA
Cybersecurity
MCA
healthcare
Leadership
Healthcare
Digital Marketing
Data Science
Others
Operations Management
Data Analytics
CXO
Skills you'll gain:
Duration:
16 Weeks
Indian School of Business
CERT - ISB Cybersecurity for Leaders Program India
Starts on
undefined
Get Details
'Our network of facilities is well-balanced and as people think about diversifying supply chains, and even think of going back to the US, I think we are well set for that. Our focus on differentiated offerings such as antibody-drug conjugate (ADCs) is seeing growth. Overall, the other businesses are also on track for that growth,' she said.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Wakefield: This Is The Truth About "No Fuss" Cremations
Golden Leaves
Undo
ADC is an area of pharmaceutical research that focuses on creating targeted cancer therapies.
Talking about the current global headwinds, Piramal said near-term macro-economic uncertainty and
biotech funding volatility
in the US are some of the significant risk factors to watch out for in the months ahead.
Live Events
On Monday, the company announced its first quarter results with a net loss of Rs 82 crore in Q1 FY26 versus net loss of Rs 89 crore a year ago. Revenue from operations fell 1% year-on-year to Rs 1,934 crore. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO business.
About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan.
Going ahead, Piramal said growth will be balanced between India, US and UK. The focus will be on broadening the customer base and getting new projects.
The company is investing $90 million to expand two of its US facilities in Lexington and Riverview.
The Lexington capability will come online in 2027, she said, and play a vital role in the company's integrated antibody-drug conjugate (ADC) development and manufacturing program.